Richard I. Steinhart, Chief Financial Officer at BioXcel Therapeutics, Inc. (BTAI), bought 500 shares at $5.00 ($3K) on 2018-11-30, disclosed to the SEC on 2018-11-30.
Open-market purchase of $2k BTAI by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| BTAI | SELL | 2024-10-03 | $4K | — | Filing → |
| BTAI | SELL | 2024-09-17 | $246 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $469 | — | Filing → |